卢克索利提尼布抑制了口服角质细胞中因干扰素-γ 诱导的 JAK/STAT 激活
Kim N Stolte1, Anna Fedorova1, Sameh Attia1
1Department of Periodontology, Oral Medicine and Oral Surgery, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Berlin, Germany.
Clinical and experimental dental research
|January 10, 2026
概括
简氏激酶 (JAK) /信号转换器和转录激活器 (STAT) 途径是口腔炎症的关键. 卢克索利提尼布有效地抑制了干扰素 (IFN-γ) 诱导的STAT1激活和HLA-DRB1表达在口腔角质细胞中,表明了治疗潜力.
科学领域:
- 口服免疫学 口服免疫学
- 分子生物学分子生物学
- 炎症研究的研究.
背景情况:
- 简氏激酶 (JAK) /信号转换器和转录激活器 (STAT) 途径与口腔炎症状况有关,如口腔平坦和牙周炎.
- 干扰素- (IFN-γ) 是一种促炎性细胞因子,激活JAK/STAT通路,导致口腔炎症.
研究的目的:
- 研究JAK1/2抑制剂鲁克索利提尼布对人类口腔角质细胞中IFN-γ诱导的炎症的影响.
- 评估鲁克索利提尼布对STAT1激活和人类白细胞抗原 (HLA) -DRB1表达的影响.
主要方法:
- 人口角质细胞 (OKG4) 被IFN-γ刺激以诱导炎症.
- 鲁克索利提尼布用于抑制IFN-γ信号传输.
- 西方涂抹,免疫光显微镜和细胞活力测试被用于分析蛋白质表达和细胞健康.
主要成果:
- 在口腔角质细胞中,IFN-γ显著上调酸化STAT1 (pSTAT1) 和HLA-DRB1的表达.
- 与ruxolitinib同时治疗有效地抑制了IFN-γ诱导的pSTAT1和HLA-DRB1上调到基线水平.
- 鲁克索利提尼布没有对口服角质细胞活力的不良影响.
结论:
- IFN-γ触发了口腔角质细胞中持续的STAT1激活和HLA-DRB1上调.
- 鲁克索利提尼布有效地抑制了这些IFN-γ介导的炎症反应.
- 针对JAK/STAT通路使用诸如ruxolitinib之类的药物对于治疗口腔炎症疾病具有前景.
相关概念视频
The JAK-STAT Signaling Pathway
11.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
11.9K
TGF - β Signaling Pathway
10.4K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.4K
PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
NF-κB-dependent Signaling Pathway
9.8K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
9.8K
Experimental RNAi
7.2K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
7.2K


